Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As the NHS prepares to substantially expand its use of robotic surgery, two major studies have found that robotic-assisted hip and knee replacement does not reduce the overall risk of repeat surgery compared with conventional surgery at five years – highlighting the importance of robust evidence as new surgical technologies are adopted at scale.

The studies, published in The BMJ, analysed more than one million hip and knee replacements recorded in the National Joint Registry between 2018 and 2024. They provide the largest real-world evaluation to date of whether robotic assistance translates into better early outcomes for patients.

The findings come at an important point for the NHS. NHS England has set out plans for a major expansion of robotic surgery over the next decade, with the number of robot-assisted procedures across different surgical specialties projected to rise from around 70,000 a year in 2023/24 to 500,000 by 2035.  If robotic systems were used for all hip and knee replacements the cost to the NHS would be substantially in excess of £100M annually.

Researchers say the studies underline the need for new surgical technologies to be evaluated against outcomes that matter to patients as they are introduced more widely.

David Murray, Professor of Orthopaedic Surgery at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, and senior author of both studies, said: 'Although robotic surgery can help with some aspects of the operation the important question is whether that ultimately leads to better outcomes for patients. In these studies, we did not find evidence of a reduction in the overall early risk of further surgery.

'That does not mean robotic surgery will have no value for hip and knee replacement, as robotic systems or other technology will improve with time.  Furthermore, these are early outcomes and there may be benefits that become apparent with longer follow-up. But as the NHS invests in and expands robotic surgery, it is important that adoption goes hand in hand with rigorous, independent evaluation so that we understand where the technology brings genuine benefit for patients and represents good value for the health service.'

In current robotic-assisted joint replacement, the surgeon remains in control of the operation, using computer and robotic technology to help plan and guide the placement of an implant. Robotic systems are intended to improve the accuracy of implant positioning,  but until now there has been limited large-scale evidence about whether these proposed technical advantages translate into fewer repeat operations.

For hip replacement, the researchers found no overall reduction in repeat surgery or mortality associated with robotic-assisted surgery. Robotic hip replacement was associated with a lower risk of further surgery for problems specifically related to poor implant positioning, but this did not translate into an overall reduction in repeat operations.

For knee replacement, there was no difference in the risk of repeat surgery between robotic-assisted and conventional procedures.

The study compares five-year outcomes and longer-term follow-up will be needed to establish whether differences in implant survival emerge over time.

The work was carried out by Mr Hasan Mohammad, now Academic Clinical Lecturer in Trauma and Orthopaedics at Queen Mary University of London.  It was begun in Oxford with Professor David Murray and Professor Andrew Judge (now at the University of Bristol) and continued by these researchers when Hasan Mohammad moved to London.

The team used a method known as target trial emulation to analyse large-scale real-world data from the National Joint Registry. The approach aims to make comparisons using observational data to more closely resemble those from a formal clinical trial by balancing groups according to known differences in patient characteristics.

Hasan said: 'This study, which uses novel methodology and represents the largest real-world analysis of its kind worldwide, provides important independent evidence for patients, surgeons and policymakers at a time when robotic hip and knee replacement surgery is being adopted rapidly. New technology should deliver meaningful benefit for patients and represent good value for a publicly funded health service.'

An accompanying editorial in The BMJ, called 'Robot assisted hip and knee arthroplasty: It is high tech, but is it better?', considers the findings in the context of increasing adoption of robotic surgery.

The researchers say continued evaluation will be important as use of the technology grows, particularly to understand longer-term outcomes and identify whether particular groups of patients or particular procedures benefit most.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.